Identification of Selective ERRγ Inverse Agonists

Author： Kim Jina Im Chun Young Yoo Eun Kyung Ma Min Jung Kim Sang-Bum Hong Eunmi Chin Jungwook Hwang Hayoung Lee Sungwoo Kim Nam Doo Jeon Jae-Han Lee In-Kyu Jeon Yong Hyun Choi Hueng-Sik Kim Seong Heon Cho Sung Jin

Publisher： MDPI

E-ISSN： 1420-3049|21|1|80-80

ISSN： 1420-3049

Source： Molecules, Vol.21, Iss.1, 2016-01, pp. : 80-80

Access to resources Favorite

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

GSK5182 (4) is currently one of the lead compounds for the development of estrogen-related receptor gamma (ERRγ) inverse agonists. Here, we report the design, synthesis, pharmacological and in vitro absorption, distribution, metabolism, excretion, toxicity (ADMET) properties of a series of compounds related to 4. Starting from 4, a series of analogs were structurally modified and their ERRγ inverse agonist activity was measured. A key pharmacophore feature of this novel class of ligands is the introduction of a heterocyclic group for A-ring substitution in the core scaffold. Among the tested compounds, several of them are potent ERRγ inverse agonists as determined by binding and functional assays. The most promising compound, 15g, had excellent binding selectivity over related subtypes (IC₅₀ = 0.44, >10, >10, and 10 μM at the ERRγ, ERRα, ERRβ, and ERα subtypes, respectively). Compound 15g also resulted in 95% transcriptional repression at a concentration of 10 μM, while still maintaining an acceptable in vitro ADMET profile. This novel class of ERRγ inverse agonists shows promise in the development of drugs targeting ERRγ-related diseases.